Nasal spray could treat Alzheimer’s disease
Researchers are exploring a new therapy to delay the progression of Alzheimer’s disease. It could be delivered in the form of a nasal spray.
Related Articles
Heat Waves and Adverse Health Events Among Dually Eligible Individuals 65 Years and Older
This time-series study assesses the association between heat waves and adverse health events among dually eligible individuals 65 years and older.
Evaluation of Airborne Chemicals from Neonatal Incubators
The FDA is evaluating the potential for exposure to airborne chemicals (formaldehyde, cyclohexanone, and other volatile chemicals) from neonatal incubators.
Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study
Objectives This work aimed to resolve the conflicting reports on Prevotellaceae abundance in the development of rheumatoid arthritis (RA) and to observe structural, functional and…
Oscar Health racks up $55M net loss as all eyes turn to ACA enhanced subsidies
Oscar Health CEO Mark Bertolini’s implied message to Republicans eager to let the Affordable Care Act’s (ACA’s) enhanced subsidies expire was clear: Do so at…
Scientists in Japan develop new SARS-CoV-2 variant detection method
Researchers at Kumamoto University have made a significant breakthrough in the fight against COVID-19 with the development of “Intelli-OVI,” a cutting-edge diagnostic tool capable of…
Google’s new AI video maker for businesses is now available on Workspace
Google Vids is rolling out now
The urgent need for clear and concise regulations on exosome-based interventions
Turner and colleagues recently argued that countries with unclear laws and regulations regarding stem cells, exosomes, and other regenerative medicine products should develop and enforce…
NeueHealth shows off ‘strongest’ earnings performance, but profitability lags
NeueHealth CEO Mike Mikan began the company’s extremely quick third-quarter earnings call highlighting its “strongest financial performance to date,” seemingly boosting its stock Nov. 7.…
The antibodies don’t work! The race to rid labs of molecules that ruin experiments
Nature – Poorly performing antibodies have plagued biomedical sciences for decades. Several fresh initiatives hope to change this.
Long COVID and recovery from Long COVID: quality of life impairments and subjective cognitive decline at a median of 2 years after initial infection – BMC Infectious Diseases
Background Recovery from SARS CoV-2 infection is expected within 3 months. Long COVID occurs after SARS-CoV-2 when symptoms are present for more than 3 months…
